Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an update.
Sino Biopharmaceutical Limited has announced the acceptance of its new indication application for the marketing of Culmerciclib Capsule, a CDK2/4/6 inhibitor, in combination with fulvestrant injection for the first-line treatment of HR-positive, HER2-negative advanced breast cancer. This acceptance by the Centre for Drug Evaluation of the National Medical Products Administration of the PRC highlights the potential of this combination therapy in different stages of advanced breast cancer treatment, aligning with authoritative guidelines that recommend such therapies for this common subtype of breast cancer.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development and marketing of innovative drugs, particularly in the oncology sector, with an emphasis on treatments for various types of cancer.
Average Trading Volume: 136,591,888
Technical Sentiment Signal: Buy
Current Market Cap: HK$96.04B
Learn more about 1177 stock on TipRanks’ Stock Analysis page.